These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. HER2 as a Predictive Biomarker and Treatment Target in Colorectal Cancer. De Cuyper A; Van Den Eynde M; Machiels JP Clin Colorectal Cancer; 2020 Jun; 19(2):65-72. PubMed ID: 32229076 [TBL] [Abstract][Full Text] [Related]
4. Prolonged Response to HER2-Directed Therapy in a Patient With HER2-Amplified, Rapidly Progressive Metastatic Colorectal Cancer. Parikh A; Atreya C; Korn WM; Venook AP J Natl Compr Canc Netw; 2017 Jan; 15(1):3-8. PubMed ID: 28040715 [TBL] [Abstract][Full Text] [Related]
5. Therapeutic landscape of advanced HER2-positive breast cancer in 2022. Gupta R; Gupta S; Antonios B; Ghimire B; Jindal V; Deol J; Gaikazian S; Huben M; Anderson J; Stender M; Jaiyesimi I Med Oncol; 2022 Oct; 39(12):258. PubMed ID: 36224475 [TBL] [Abstract][Full Text] [Related]
6. Incidence of adverse events with therapies targeting HER2-positive metastatic breast cancer: a literature review. Perez EA; Dang C; Lee C; Singh J; Wang K; Layton JB; Gilsenan A; Hackshaw MD; Cortes J Breast Cancer Res Treat; 2022 Jul; 194(1):1-11. PubMed ID: 35587323 [TBL] [Abstract][Full Text] [Related]
7. Trastuzumab plus pertuzumab for HER2-amplified advanced colorectal cancer: Results from the drug rediscovery protocol (DRUP). Spiekman IAC; Zeverijn LJ; Geurts BS; Verkerk K; Haj Mohammad SF; van der Noort V; Roepman P; de Leng WWJ; Jansen AML; Gootjes EC; de Groot DA; Kerver ED; van Voorthuizen T; Roodhart JML; Valkenburg-van Iersel LBJ; Gelderblom H; Voest EE; Verheul HMW Eur J Cancer; 2024 May; 202():113988. PubMed ID: 38471288 [TBL] [Abstract][Full Text] [Related]
8. [Targeting HER2 in colorectal cancer]. Spitzer E; Cervera P; André T; Cohen R Bull Cancer; 2023 Apr; 110(4):402-411. PubMed ID: 36870811 [TBL] [Abstract][Full Text] [Related]
9. Efficacy of tucatinib for HER2-positive metastatic breast cancer after HER2-targeted therapy: a network meta-analysis. DeBusk K; Abeysinghe S; Vickers A; Nangia A; Bell J; Ike C; Forero-Torres A; Blahna MT Future Oncol; 2021 Nov; 17(33):4635-4647. PubMed ID: 34463120 [TBL] [Abstract][Full Text] [Related]
10. Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models. Belli V; Matrone N; Napolitano S; Migliardi G; Cottino F; Bertotti A; Trusolino L; Martinelli E; Morgillo F; Ciardiello D; De Falco V; Giunta EF; Bracale U; Ciardiello F; Troiani T J Exp Clin Cancer Res; 2019 Jun; 38(1):236. PubMed ID: 31164152 [TBL] [Abstract][Full Text] [Related]
11. Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial. Sartore-Bianchi A; Lonardi S; Martino C; Fenocchio E; Tosi F; Ghezzi S; Leone F; Bergamo F; Zagonel V; Ciardiello F; Ardizzoni A; Amatu A; Bencardino K; Valtorta E; Grassi E; Torri V; Bonoldi E; Sapino A; Vanzulli A; Regge D; Cappello G; Bardelli A; Trusolino L; Marsoni S; Siena S ESMO Open; 2020 Sep; 5(5):e000911. PubMed ID: 32988996 [TBL] [Abstract][Full Text] [Related]
12. Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Current Treatment Standards and Future Perspectives. Dormann C Breast Care (Basel); 2020 Dec; 15(6):570-578. PubMed ID: 33447230 [TBL] [Abstract][Full Text] [Related]
13. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. Meric-Bernstam F; Hurwitz H; Raghav KPS; McWilliams RR; Fakih M; VanderWalde A; Swanton C; Kurzrock R; Burris H; Sweeney C; Bose R; Spigel DR; Beattie MS; Blotner S; Stone A; Schulze K; Cuchelkar V; Hainsworth J Lancet Oncol; 2019 Apr; 20(4):518-530. PubMed ID: 30857956 [TBL] [Abstract][Full Text] [Related]
14. Trastuzumab-containing regimens for metastatic breast cancer. Balduzzi S; Mantarro S; Guarneri V; Tagliabue L; Pistotti V; Moja L; D'Amico R Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD006242. PubMed ID: 24919460 [TBL] [Abstract][Full Text] [Related]
15. Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2-Positive Metastatic Breast Cancer: A Phase 1b Clinical Trial. Borges VF; Ferrario C; Aucoin N; Falkson C; Khan Q; Krop I; Welch S; Conlin A; Chaves J; Bedard PL; Chamberlain M; Gray T; Vo A; Hamilton E JAMA Oncol; 2018 Sep; 4(9):1214-1220. PubMed ID: 29955792 [TBL] [Abstract][Full Text] [Related]
16. HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer. Miller K; Cortes J; Hurvitz SA; Krop IE; Tripathy D; Verma S; Riahi K; Reynolds JG; Wickham TJ; Molnar I; Yardley DA BMC Cancer; 2016 Jun; 16():352. PubMed ID: 27259714 [TBL] [Abstract][Full Text] [Related]
17. Targeting human EGFR 2 (HER2) in salivary gland carcinoma. Wotman M; El-Naggar A; Ferrarotto R Expert Rev Anticancer Ther; 2023 Jun; 23(6):573-582. PubMed ID: 37114470 [TBL] [Abstract][Full Text] [Related]
18. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study. Tan AR; Im SA; Mattar A; Colomer R; Stroyakovskii D; Nowecki Z; De Laurentiis M; Pierga JY; Jung KH; Schem C; Hogea A; Badovinac Crnjevic T; Heeson S; Shivhare M; Kirschbrown WP; Restuccia E; Jackisch C; Lancet Oncol; 2021 Jan; 22(1):85-97. PubMed ID: 33357420 [TBL] [Abstract][Full Text] [Related]
19. Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3. Ross JS; Fakih M; Ali SM; Elvin JA; Schrock AB; Suh J; Vergilio JA; Ramkissoon S; Severson E; Daniel S; Fabrizio D; Frampton G; Sun J; Miller VA; Stephens PJ; Gay LM Cancer; 2018 Apr; 124(7):1358-1373. PubMed ID: 29338072 [TBL] [Abstract][Full Text] [Related]